Figure 3.
Anti-C7 inhibited anti-MHC 1–induced murine TRALI. Wild-type BALB/c male mice were treated with mAbs against MHC 1 (anti-MHC 1: mAb 34-1-2S) for TRALI induction as indicated. In the prophylactic approach, anti-C7 (dose: 1 mg/200 μL in PBS) was injected before TRALI induction with mAb 34-1-2S (4.5 mg/kg). In the therapeutic approach, TRALI was first induced with mAb 34-1-2S (4.5 mg/kg), then treated with anti-C7 (dose: 1 mg/200 μL in PBS) after TRALI. PBS was treated as a control. Rectal temperatures (A) and lung W/D weight ratios (B) were measured as described earlier (n = 5 in each cohort). Statistical analysis was performed with 1-way analysis of variance with Bonferroni correction for multiple comparisons. Each dot represents 1 mouse and error bars represent the standard deviations. ∗∗∗∗P < .0001; ∗∗∗P < .001; ∗∗P < .01.

Anti-C7 inhibited anti-MHC 1–induced murine TRALI. Wild-type BALB/c male mice were treated with mAbs against MHC 1 (anti-MHC 1: mAb 34-1-2S) for TRALI induction as indicated. In the prophylactic approach, anti-C7 (dose: 1 mg/200 μL in PBS) was injected before TRALI induction with mAb 34-1-2S (4.5 mg/kg). In the therapeutic approach, TRALI was first induced with mAb 34-1-2S (4.5 mg/kg), then treated with anti-C7 (dose: 1 mg/200 μL in PBS) after TRALI. PBS was treated as a control. Rectal temperatures (A) and lung W/D weight ratios (B) were measured as described earlier (n = 5 in each cohort). Statistical analysis was performed with 1-way analysis of variance with Bonferroni correction for multiple comparisons. Each dot represents 1 mouse and error bars represent the standard deviations. ∗∗∗∗P < .0001; ∗∗∗P < .001; ∗∗P < .01.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal